Identification of human telomerase reverse transcriptase–derived peptides that induce HLA-A24–restricted antileukemia cytotoxic T lymphocytes

DOI PDF 被引用文献9件
  • Junko Arai
    From the First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime, Japan.
  • Masaki Yasukawa
    From the First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime, Japan.
  • Hideki Ohminami
    From the First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime, Japan.
  • Miki Kakimoto
    From the First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime, Japan.
  • Atsuhiko Hasegawa
    From the First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime, Japan.
  • Shigeru Fujita
    From the First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime, Japan.

抄録

<jats:title>Abstract</jats:title><jats:p>Human telomerase reverse transcriptase (hTERT) is considered a potential target for cancer immunotherapy because it is preferentially expressed in malignant cells. hTERT-derived peptides carrying motifs for HLA-A24 (HLA-A*2402), the most common allele among Japanese and also frequently present in persons of European descent, were examined for their capacity to elicit antileukemia cytotoxic T lymphocytes (CTLs). Two of the 5 peptides tested, VYAETKHFL and VYGFVRACL, appeared capable of generating hTERT peptide-specific and HLA-A24–restricted CTLs. The CD8+ CTL clones specific for these hTERT peptides exerted cytotoxicity against leukemia cells in an HLA-A24–restricted manner. This cytotoxicity was inhibited by the addition of hTERT peptide-loaded autologous cells, suggesting that hTERT is naturally processed in leukemia cells and that hTERT-derived peptides are expressed on these cells and are recognized by CTLs in the context of HLA-A24. Taken together with the currently identified HLA-A2–restricted CTL epitopes derived from hTERT, identification of new CTL epitopes presented by HLA-A24 increases the feasibility of immunotherapy for leukemia using hTERT-derived peptides.</jats:p>

収録刊行物

  • Blood

    Blood 97 (9), 2903-2907, 2001-05-01

    American Society of Hematology

被引用文献 (9)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ